<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931108</url>
  </required_header>
  <id_info>
    <org_study_id>NAC-BPV</org_study_id>
    <nct_id>NCT04931108</nct_id>
  </id_info>
  <brief_title>The Effect of Nitrendipine/Atenolol Combination on Blood Pressure Variability.</brief_title>
  <official_title>The Effect of Nitrendipine/Atenolol Combination on Blood Pressure Variability of Patients With Grade 1 Hypertension Compared With Nitrendipine or Atenolol Monotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Study name: The Effect of Nitrendipine/Atenolol Combination on Blood Pressure&#xD;
           Variability.&#xD;
&#xD;
        2. Medicine: Nitrendipine/Atenolol; Nitrendipine; Atenolol.&#xD;
&#xD;
        3. Rationale: Blood pressure variability correlates with cardiovascular events and&#xD;
           target-organ damage in hypertensive patients. Nitrendipine/Atenolol has obvious&#xD;
           advantages in reducing blood pressure variability in hypertensive rats, but the effect&#xD;
           of this combination on hypertensive patients is still unknown.&#xD;
&#xD;
        4. Objective: To evaluate the effect of nitrendipine/atenolol on blood pressure variability&#xD;
           of patients with Grade 1 hypertension compared with nitrendipine or atenolol&#xD;
           monotherapy.&#xD;
&#xD;
        5. Study design: This study is a cross-over, randomized, controlled clinical trial with two&#xD;
           equally sized treatment groups: Nitrendipine/Atenolol (5mg/10mg); Nitrendipine (10mg) or&#xD;
           atenolol (25mg).&#xD;
&#xD;
        6. Study population: Men and Women aged 30-65 years (n=32) meeting the inclusion/exclusion&#xD;
           criteria.&#xD;
&#xD;
        7. Randomization and cross-over design: Eligible patients will be randomly divided into two&#xD;
           groups. Half of patients will take nitrendipine/atenolol (5/10mg) once daily for 6 weeks&#xD;
           first, and then evenly turn into nitrendipine (10mg) or atenolol (25mg) once daily for 6&#xD;
           weeks. Another half of patients will evenly take nitrendipine (10mg) or atenolol (25mg)&#xD;
           first, and turn into nitrendipine/atenolol (5/10mg) next.&#xD;
&#xD;
        8. Follow up: 14 weeks.&#xD;
&#xD;
        9. Sample size: a total of 32 patients should be enrolled.&#xD;
&#xD;
       10. Timeline: After obtaining the approval of Ethics Committee of Ruijin Hospital in April&#xD;
           2021, recruitment will start. Patients enrollment and follow-up will be performed&#xD;
           between June 2021 to June 2022.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Study name: The effect of Nitrendipine/Atenolol combination on blood pressure&#xD;
           variability of patients with Grade 1 hypertension compared with nitrendipine or atenolol&#xD;
           monotherapy.&#xD;
&#xD;
        2. Medicine: Nitrendipine/Atenolol (5/10mg tablet); Nitrendipine (10mg tablet); Atenolol&#xD;
           (25mg tablet)&#xD;
&#xD;
        3. Rationale: Blood pressure variability correlates with cardiovascular events and&#xD;
           target-organ damage in hypertensive patients. Nitrendipine/Atenolol has obvious&#xD;
           advantages in reducing blood pressure variability in hypertensive rats, but the effect&#xD;
           of this combination on hypertensive patients is still unknown.&#xD;
&#xD;
        4. Objective: To evaluate the effect of nitrendipine/atenolol on blood pressure variability&#xD;
           of patients with Grade 1 hypertension compared with nitrendipine or atenolol&#xD;
           monotherapy.&#xD;
&#xD;
        5. Study design: This study is a cross-over, randomized, controlled clinical trial with two&#xD;
           equally sized treatment groups: Nitrendipine/Atenolol (5mg/10mg); Nitrendipine (10mg) or&#xD;
           atenolol (25mg).&#xD;
&#xD;
        6. Study population: Eligible patients (n=32) should be men or women aged 30-65 years.&#xD;
           Untreated patients diagnosed as essential hypertension, whose daytime systolic blood&#xD;
           pressure ≥ 135mmHg and/or daytime diastolic blood pressure ≥ 85mmHg, and standard&#xD;
           deviation (SD)≥13mmHg will be recruited.&#xD;
&#xD;
        7. Randomization and cross-over design: Eligible patients will be randomly divided into two&#xD;
           groups. Half of patients will take nitrendipine/atenolol (5/10mg) once daily for 6 weeks&#xD;
           first, and then evenly turn into nitrendipine (10mg) or atenolol (25mg) once daily for 6&#xD;
           weeks. Another half of patients will evenly take nitrendipine (10mg) or atenolol (25mg)&#xD;
           first, and turn into nitrendipine/atenolol (5/10mg) next.&#xD;
&#xD;
        8. Follow up: 14 weeks. 1 week for screening period, 6 weeks for the first period of&#xD;
           treatment, 1 week for wash-out period, and 6 weeks for the second period of treatment.&#xD;
&#xD;
        9. Sample size: a total of 32 patients should be enrolled.&#xD;
&#xD;
       10. Timeline: After obtaining the approval of Ethics Committee of Ruijin Hospital in April&#xD;
           2021, recruitment will start. Patients enrollment and follow-up will be performed&#xD;
           between June 2021 to June 2022.&#xD;
&#xD;
       11. Organization: The Centre for Epidemiological Studies and Clinical Trials, Ruijin&#xD;
           Hospital, Shanghai, China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Half of patients will take nitrendipine/atenolol (5/10mg) once daily for 6 weeks first, and then evenly turn into nitrendipine (10mg) or atenolol (25mg) once daily for 6 weeks. Another half of patients will evenly take nitrendipine (10mg) or atenolol (25mg) first, and turn into nitrendipine/atenolol (5/10mg) next.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ambulatory systolic blood pressure variability 1</measure>
    <time_frame>The first 6 weeks of treatment.</time_frame>
    <description>Including the average real variability (ARV), the coefficient of variation (CV),and the standard deviation (SD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ambulatory systolic blood pressure variability 2</measure>
    <time_frame>The second 6 weeks of cross-over treatment.</time_frame>
    <description>Including the average real variability (ARV), the coefficient of variation (CV),and the standard deviation (SD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ambulatory diastolic blood pressure variability 1</measure>
    <time_frame>The first 6 weeks of treatment.</time_frame>
    <description>Including the average real variability (ARV), the coefficient of variation (CV),and the standard deviation (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory diastolic blood pressure variability 2</measure>
    <time_frame>The second 6 weeks of cross-over treatment.</time_frame>
    <description>Including the average real variability (ARV), the coefficient of variation (CV),and the standard deviation (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure 1</measure>
    <time_frame>The first 6 weeks of treatment.</time_frame>
    <description>Including ambulatory blood pressure over 24 hours, daytime and nighttime.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure 2</measure>
    <time_frame>The second 6 weeks of cross-over treatment.</time_frame>
    <description>Including ambulatory blood pressure over 24 hours, daytime and nighttime.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One pill of nitrendipine/atenolol combination (5/10mg) once daily for 6 weeks first, and followed by monotherapy for another 6 weeks, when patients will evenly assigned to one pill of nitrendipine (10mg) or one pill of atenolol (25mg) once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy for 6 weeks first, when patients will evenly assigned to one pill of nitrendipine (10mg) or one pill of atenolol (25mg) once daily, followed by one pill of nitrendipine/atenolol combination (5/10mg) once daily for another 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrendipine/Atenolol</intervention_name>
    <description>Nitrendipine/Atenolol 5mg/10mg single-pill combination, oral tablet, one pill daily.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <other_name>Nitrendipine and Atenolol Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrendipine</intervention_name>
    <description>Nitrendipine 5mg, oral tablet, one pill daily.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <other_name>Nitrendipine Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>Atenolol 25mg, oral tablet, one pill daily.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <other_name>Atenolol Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or Women.&#xD;
&#xD;
          -  Aged 30-65 years.&#xD;
&#xD;
          -  Ambulatory systolic blood pressure ≥ 135 mmHg and/or diastolic blood pressure ≥ 85&#xD;
             mmHg.&#xD;
&#xD;
          -  Ambulatory daytime systolic blood pressure standard deviation (SD)≥13mmHg.&#xD;
&#xD;
          -  Never took antihypertensive drugs.&#xD;
&#xD;
          -  Signed the written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under antihypertensive treatments.&#xD;
&#xD;
          -  Clinic systolic blood pressure ≥ 160mmHg and/or diastolic blood pressure ≥ 100mmHg.&#xD;
&#xD;
          -  Contraindications to the treatment of drugs, including hypersensitivity reaction,&#xD;
             bradycardia, asthma, etc.&#xD;
&#xD;
          -  Any cardiovascular disease except hypertension.&#xD;
&#xD;
          -  Suspected or confirmed secondary hypertension.&#xD;
&#xD;
          -  Poor compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Ji-Guang Wang</investigator_full_name>
    <investigator_title>Director of the Shanghai Institute of Hypertension</investigator_title>
  </responsible_party>
  <keyword>blood pressure variability</keyword>
  <keyword>nitrendipine</keyword>
  <keyword>atenolol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Nitrendipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

